Sufficiency for inducible Caspase-9 safety switch in human pluripotent stem cells and disease cells
Toshinobu Nishimura(Stanford University), Hiromitsu Nakauchi(Japan Science and Technology Agency), Manami Ohtaka(National Institute of Advanced Industrial Science and Technology), Michael L. Cleary(Stanford University), Daiki Karigane(Keio University), Renata M. Martin(Stanford University), Scott R. Burrows(QIMR Berghofer Medical Research Institute), Fabian P. Suchy(Stanford University), Masayuki Iwasaki(Tokyo Women's Medical University), Ravindra Majeti(California Institute for Regenerative Medicine), Yusuke Takahashi(Stanford University), Shinichiro Monobe(Stanford University), Akira Shibuya(University of Tsukuba), Haojun Xu(University of Tsukuba), Brandon Saavedra(Stanford University), Mahito Nakanishi(Stem Cell Institute)
Cited by 13
Related Papers
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers
|Journal of Clinical Oncology|2019|590
Development of Defective and Persistent Sendai Virus Vector
|Journal of Biological Chemistry|2010|373
NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo
|Journal of Clinical Investigation|2009|331
Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers
|Hepatology|2012|195
Rapid Chromatin Switch in the Direct Reprogramming of Fibroblasts to Neurons
|Cell Reports|2017|146